Need Help?

Longitudinal therapy monitoring of ALK-positive non-small cell lung cancer (copy number, cell-free DNA)

Clinical courses of non-small cell lung cancer patients with ALK rearrangements (ALK+ NSCLC) vary widely. We analyzed 271 longitudinal plasma samples from 73 patients with advanced ALK+ NSCLC treated with ALK tyrosine kinase inhibitors by combined hybrid-capture-based targeted sequencing (average 4,100x coverage) for mutation analysis and shallow whole genome sequencing (0.5x coverage) for global copy number profiling from cfDNA.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001006297 270
EGAD00001006298 268
EGAD00001007817 Illumina HiSeq 4000 NextSeq 500 400
Publications Citations
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
EBioMedicine 62: 2020 103103